stockrowGeron Corporation
GERN Healthcare Biotechnology
Geron Corporation’s revenue for fiscal 2025 (year ended December 2025) was $183.9 million, up 138.8% from fiscal 2024.
- Revenue
- +27.5%
- EPS
- +106.7%
- Free cash flow
- +176.1%
- Total debt
- +0.99%
Quarter to September 2026, against a year earlier
Follow GERN
Alert me
Geron Corporation (GERN) EV/Sales
As of 6 November 2026, Geron Corporation (GERN) trades at a EV/Sales of 2.6×. Over the past ten years it has ranged from 2.3× (October 2026) to 7,216× (March 2024); the current reading is higher than 0% of that period. That is below the Biotechnology industry median of 9.0× and below the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 3.9× | (85.60%) |
| FY2024 | 26.9× | (99.34%) |
| FY2023 | 4,086× | 207.49% |
| FY2022 | 1,329× | 594.91% |
| FY2021 | 191× | (81.39%) |
| FY2020 | 1,027× | 288.69% |
| FY2019 | 264× | 2,076.11% |
| FY2018 | 12.1× | (93.31%) |
| FY2017 | 181× | 399.92% |
| FY2016 | 36.3× | 102.83% |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2026 | 3.4× | (8.08%) |
| Jun 2026 | 3.7× | (18.06%) |
| Mar 2026 | 4.5× | 15.27% |
| Dec 2025 | 3.9× | (1.78%) |
| 43 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| HELP Cybin Inc. compare | n/m |
| AVBP ArriVent BioPharma, Inc. compare | n/m |
| IMMX Immix Biopharma, Inc. compare | n/m |
| KURA Kura Oncology, Inc. compare | 1.7× |
| GERN Geron Corporation | 2.6× |
| FDMT 4D Molecular Therapeutics, Inc. compare | 5.7× |
| DBVT DBV Technologies S.A. compare | 211× |
| DSGN Design Therapeutics, Inc. compare | 1,919× |
| CADL Candel Therapeutics, Inc. compare | 3,940× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)